| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2010: ¥1,235,000 (Direct Cost: ¥950,000、Indirect Cost: ¥285,000)
Fiscal Year 2009: ¥1,365,000 (Direct Cost: ¥1,050,000、Indirect Cost: ¥315,000)
|
|---|
| Research Abstract |
It has been demonstrated that CD40-activated B (CD40-B) cells are potent antigen presenting cells that can be expanded significantly ex vivo.
Several methods to antigen load CD40-Bs to generate viral or tumor-antigen specific CD8+ T cells have been identified. However, it is unclear how CD40-Bs take up and process exogenous antigen in an B cell receptor independent manner to stimulate CD4+ T cells. CD4+ T cells specific for multiple epitopes were successfully generated in stimulation with CD40-B cells pulsed with recombinant protein. In addition, CD40-Bs were able to be easily transfected with in vitro transcribed-mRNA. CD40-B cells are thought to be useful in cellular therapy.
|
